Vividion Therapeutics, Inc.

Activation of the transcription factor NRF2 is correlated with certain types of aggressive, treatment-resistant cancers and poor patient outcomes. Transcription factors, however, are notoriously challenging to drug, and to date, no direct NRF2 antagonistic therapies exist. Using our unique covalent-first #chemoproteomics screening approach, we have identified a first-in-class NRF2 inhibitor that acts by a new mechanism to regulate this transcriptional circuit and dramatically degrade NRF2. Learn more about this work that is supporting our ongoing Phase 1 clinical trial, which has the potential to dramatically shift the treatment paradigm of NRF2-activated cancers. #CancerResearch #Biotechnology #teamVividion

This week at the RAS-Targeted Drug Development Summit, Joseph Klebba, Associate Director Oncology Early Discovery Sciences, will present on small molecules Vividion has optimized to disrupt the PI3Kα/AKT pathway that is critical to RAS-activated cancers. These small molecules specifically disrupt the RAS-PI3Kα interaction, blocking this key signaling cascade while avoiding the toxicities typically encountered with direct lipid kinase inhibitors. Join us for our latest pre-clinical data, including patient-derived xenografts.

Despite progress in understanding cancer drivers and how to intervene, 90% of disease-causing proteins remain undrugged. Closing this gap is a critical unmet need for patients that we are addressing every day at Vividion.??? ? This #WorldCancerResearchDay, we’re highlighting our commitment to improving the lives of patients by pioneering new methods to target hard-to-reach disease targets and developing novel treatments that shape the future of cancer care.?? ? Join us in honoring all the groundbreaking researchers who are working tirelessly to make a difference. ? #CancerResearch #Biotechnology??

We are excited to launch our new “Behind the Science” series featuring one-on-one conversations with the people driving Vividion’s culture of innovation. This series will showcase our team’s pioneering work, shed light on cutting-edge research, and provide a behind-the-scenes look at our company and the scientific approach that powers it. ? In our first article, we’re thrilled to feature Vivdion CEO Aleksandra Rizo's conversation with David Weinstein, VP of Chemistry. Read more to learn about his upcoming presentation at the American Chemical Society’s Fall 2024 meeting, where he’ll unveil the first small molecule activator of Kelch-like ECH associated protein 1 (KEAP1).

What a beautiful day to celebrate the dreams and aspirations of the future stars of biotech! We were delighted to join with Life Science Cares San Diego to host an afternoon of lively conversation and career networking for the 2024 Project Onramp cohort.? ? Project Onramp connects motivated college students from diverse backgrounds to paid internships hosted at life science companies, where they gain exposure to opportunities in the field, cultivate a network of peers, and acquire important career and life skills. We are proud to partner with Project Onramp and do our part to foster a rich and inclusive talent pipeline into the biotech industry.? ? Remarking on the event, Vividion CEO Aleksandra Rizo said, “Life Science Cares is an incredibly valued partner to us, and programs like Project Onramp are a testament to the organization’s commitment to helping students in science and biotech gain invaluable professional skills with lasting impact. We’re especially grateful for the San Diego chapter of LSC, which enables us to collectively join together to support the future leaders of our very own community, our home base, that powers Vividion’s mission to transform patient care.”?? ? Thank you to everyone who attended. We are grateful for the opportunity to support the extraordinary talent and passion of the San Diego life science community we call home.? ? #LifeScienceCaresSanDiego #ProjectOnramp #MentorshipMatters #biotech #science?

Happy #NationalInternDay! Summer in San Diego means blue skies and new horizons for our student interns at Vividion. We’ve enjoyed getting to know these future stars of science and giving them an inside look at the world of drug discovery and development. Check out photos from one recent event, where the interns joined with their summer mentors for a fun – and highly competitive – Lego-building race.

Vividion is expanding our presence in San Diego! ? We’re excited to unveil our future corporate headquarters and research and development center, where we will continue leading innovation in chemoproteomics-enabled drug discovery and advancing our expansive portfolio of clinical and preclinical programs.? ? Read more in today’s news: https://bit.ly/4dbeJ4f

WRN helicase is a promising target for treatment of cancers with microsatellite instability (MSI), which occurs in certain cancer subtypes. At the?Cancer Molecular Therapeutics Research Association 2024 Annual Meeting, Vividion Chief Scientific Officer?Matt Patricelli will present our chemoproteomics approach?that?led to the discovery of a novel covalent allosteric inhibitor of WRN. One of the first inhibitors to target WRN to make it to the clinic, it is now being evaluated in a Roche-sponsored Phase 1 first-in-human clinical trial. #CMTRA?#CancerResearch

We wish everyone a #HappyPride! Join us in celebrating the accomplishments of the LGBTQIA+ community and continuing each day forward to foster an inclusive society for all.? ? #Pride2024

Vividion Chief Scientific Officer Matt Patricelli will present at the American Association for Cancer Research (AACR) special conference exploring synthetic vulnerability as a strategy enabling therapeutic development for difficult-to-treat cancers, being held June 10-13 in Montreal. His talk will focus on the discovery of VVD-133214 (also known as RO7589831), a covalent allosteric inhibitor of Werner helicase (WRN), which is currently being evaluated in a Roche-sponsored Phase 1 first-in-human clinical trial.